Skip to main content

Table 3 Anterior pituitary function at presentation and during follow-up

From: Clinicopathological features and BRAFV600E mutations in patients with isolated hypothalamic-pituitary Langerhans cell histiocytosis

No.

At presentation

Follow-up

 

AP deficiency

GH (ng/mL, <2.5)

IGF1 (ng/mL, 74–388)

ACTH (pg/mL, 0–46)

Cortisol (μg/dL, 4–25)

LH (IU/L, 1.2–58.64)

FSH (IU/L, 1.27–113.59)

PRL (ng/mL, 2.74–26.72)

E2 (pg/mL, 20–273)

T (ng/dL, 0.1–7.8)

TSH (μIU/mL,0.38–4.34)

FT4 (ng/dL,0.81–1.89)

AP deficiency

1

Panhypopituitary

0.2

25

15.29

0.81

0

0.2

15.84

10.4

11.2

0.202

0.56

Panhypopituitary

2

Not impaired

0.5

129

28. 6

13.51

3.12

4.91

37.1

44

0.19

1.54

1.22

Not impaired

3

GH, LH-FSH deficiency

<0.05

72

26.3

12.05

0.43

0.36

17.39

25

<0.1

8.485

1.01

Panhypopituitary

4

Not impaired

1.4

198

30.6

12.9

2.63

1.0

15.6

11.8

360.8

2.662

1.380

NA

5

Panhypopituitary

<0.05

44

7.6

0.74

0

0.3

11.7

10.2

5.2

2.539

0.60

Panhypopituitary

6

Not impaired

0.2

381

51.3

13.65

4.7

4.42

18.14

56

2.11

2.581

1.333

Not impaired

7

Panhypopituitary

0.12

68

7.6

0.2

5.2

1.67

51.22

0.09

0.73

0.26

0.77

Panhypopituitary

  1. AP anterior pituitary, GH growth hormone, IGF1 insulin-like growth factor-1, ACTH adrenocorticotropic hormone, LH luteinizing hormone, FSH follicle-stimulating hormone, PRL prolactin, E2 oestradiol, T testosterone, TSH thyroid-stimulating hormone, FT4 free thyroxine